BioNTech (NASDAQ:BNTX) Cut to Market Perform at Leerink Partners

Leerink Partners lowered shares of BioNTech (NASDAQ:BNTX) from an outperform rating to a market perform rating in a research report sent to investors on Monday morning, MarketBeat.com reports. The firm currently has $113.00 target price on the stock.

Several other research firms have also commented on BNTX. Berenberg Bank reissued a “buy” rating on shares of BioNTech in a research note on Friday, January 23rd. TD Cowen reiterated a “hold” rating on shares of BioNTech in a report on Monday, November 3rd. UBS Group upgraded BioNTech to a “hold” rating in a research note on Thursday, December 4th. Morgan Stanley reiterated an “overweight” rating and set a $134.00 price objective on shares of BioNTech in a research note on Monday, November 3rd. Finally, Bank of America dropped their target price on BioNTech from $134.00 to $130.00 and set a “buy” rating on the stock in a report on Wednesday, October 22nd. Eleven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $140.10.

BioNTech Trading Up 0.5%

BNTX opened at $108.77 on Monday. The company has a quick ratio of 7.02, a current ratio of 7.12 and a debt-to-equity ratio of 0.01. BioNTech has a 52 week low of $81.20 and a 52 week high of $124.49. The stock has a market cap of $24.49 billion, a PE ratio of -41.36 and a beta of 1.49. The business has a 50 day moving average of $101.63 and a 200-day moving average of $103.79.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). BioNTech had a negative return on equity of 3.03% and a negative net margin of 17.91%.The firm had revenue of $1.78 billion during the quarter, compared to the consensus estimate of $1.21 billion. During the same quarter last year, the company posted $0.81 EPS. BioNTech’s revenue for the quarter was up 22.0% compared to the same quarter last year. Equities research analysts predict that BioNTech will post -3.88 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Institutional investors have recently modified their holdings of the business. Royal Bank of Canada raised its position in BioNTech by 95.9% in the 1st quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock worth $653,000 after buying an additional 3,514 shares during the last quarter. NewEdge Advisors LLC bought a new stake in shares of BioNTech in the first quarter worth approximately $167,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of BioNTech by 14.9% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,109 shares of the company’s stock worth $437,000 after acquiring an additional 533 shares during the period. Shell Asset Management Co. raised its holdings in shares of BioNTech by 15.3% during the second quarter. Shell Asset Management Co. now owns 40,610 shares of the company’s stock valued at $4,324,000 after purchasing an additional 5,398 shares during the last quarter. Finally, Aberdeen Group plc lifted its position in BioNTech by 87.2% during the second quarter. Aberdeen Group plc now owns 721,928 shares of the company’s stock valued at $76,864,000 after purchasing an additional 336,260 shares during the period. 15.52% of the stock is owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.